Provided by Tiger Fintech (Singapore) Pte. Ltd.

Larimar Therapeutics, Inc.

2.38
+0.370018.41%
Post-market: 2.38-0.0001+0.00%17:35 EDT
Volume:2.33M
Turnover:5.35M
Market Cap:152.39M
PE:-1.81
High:2.44
Open:2.04
Low:2.00
Close:2.01
Loading ...

Larimar Therapeutics Begins Dosing Adolescents in Friedreich's Ataxia Treatment Study

MT Newswires Live
·
24 Jan

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-in Study for Patients With Friedreich’s Ataxia

THOMSON REUTERS
·
24 Jan

Larimar Therapeutics Inc - to Initiate Cohort of Children 2-11 Years Old in 1H 2025

THOMSON REUTERS
·
24 Jan

SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia

Zacks
·
08 Jan

Oppenheimer Reaffirms Their Buy Rating on Larimar Therapeutics (LRMR)

TIPRANKS
·
17 Dec 2024

Larimar Therapeutics announces initial data from OLE study of nomlabofusp

TipRanks
·
17 Dec 2024

Market ‘misinterpreting’ Larimar data, selloff ‘overdone,’ says Citi

TIPRANKS
·
17 Dec 2024

Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)

TIPRANKS
·
17 Dec 2024

Larimar Therapeutics selloff a buying opportunity, says JonesResearch

TIPRANKS
·
17 Dec 2024

Larimar Therapeutics trading resumes

TIPRANKS
·
16 Dec 2024

Larimar Therapeutics trading halted, volatility trading pause

TIPRANKS
·
16 Dec 2024

Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes

MT Newswires Live
·
16 Dec 2024

BRIEF-Larimar Therapeutics Announces Positive Initial Data From Ongoing Long-Term Open Label Extension Study

Reuters
·
16 Dec 2024

Larimar Therapeutics Inc: Projected Runway Into Q2 of 2026

THOMSON REUTERS
·
16 Dec 2024

Larimar Therapeutics Inc - Nomlabofusp 25 Mg Well Tolerated in 14 Participants for up to 260 Days

THOMSON REUTERS
·
16 Dec 2024

Larimar Therapeutics Inc - Bla Submission Targeted for 2H 2025 for Potential Accelerated Approval

THOMSON REUTERS
·
16 Dec 2024

Larimar Therapeutics Announces Positive Initial Data From Ongoing Long-Term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

THOMSON REUTERS
·
16 Dec 2024

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Larimar Therapeutics (LRMR) and Merus (MRUS)

TIPRANKS
·
06 Dec 2024

Larimar Therapeutics Shares Hit Session Low With Volume Pickup, Last Down 5.3% at $6.04

THOMSON REUTERS
·
21 Nov 2024

Larimar Therapeutics presents Phase 1 and 2 dose studies of nomlabofusp

TIPRANKS
·
18 Nov 2024